Salem Investment Counselors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$175K Buy
1,389
+120
+9% +$15.8K ﹤0.01% 420
2026
Q1
$177K Buy
+1,269
New +$178K 0.01% 402
2025
Q4
Sell
-551
Closed -$61.2K 685
2025
Q3
$61.2K Buy
551
+244
+79% +$27.7K ﹤0.01% 561
2025
Q2
$34K Sell
307
-183
-37% -$19.5K ﹤0.01% 650
2025
Q1
$54.9K Buy
490
+380
+345% +$39.2K ﹤0.01% 559
2024
Q4
$10.2K Sell
110
-497
-82% -$44.7K ﹤0.01% 835
2024
Q3
$50.9K Hold
607
﹤0.01% 574
2024
Q2
$41.6K Hold
607
﹤0.01% 598
2024
Q1
$44.5K Sell
607
-398
-40% -$30.6K ﹤0.01% 576
2023
Q4
$81.4K Sell
1,005
-65
-6% -$5.06K ﹤0.01% 472
2023
Q3
$80.2K Hold
1,070
﹤0.01% 453
2023
Q2
$82.5K Buy
1,070
+198
+23% +$15.8K ﹤0.01% 449
2023
Q1
$72.3K Buy
872
+350
+67% +$29K ﹤0.01% 473
2022
Q4
$44.8K Sell
522
-30
-5% -$2.38K ﹤0.01% 537
2022
Q3
$34K Buy
552
+30
+6% +$1.89K ﹤0.01% 540
2022
Q2
$32K Hold
522
﹤0.01% 585
2022
Q1
$31K Buy
522
+22
+4% +$1.41K ﹤0.01% 587
2021
Q4
$36K Hold
500
﹤0.01% 613
2021
Q3
$35K Hold
500
﹤0.01% 555
2021
Q2
$34K Hold
500
﹤0.01% 539
2021
Q1
$32K Sell
500
-71
-12% -$4.58K ﹤0.01% 518
2020
Q4
$33K Buy
571
+71
+14% +$4.28K ﹤0.01% 509
2020
Q3
$32K Hold
500
﹤0.01% 435
2020
Q2
$38K Sell
500
-685
-58% -$52.5K ﹤0.01% 398
2020
Q1
$89K Buy
1,185
+565
+91% +$39K 0.01% 282
2019
Q4
$40K Sell
620
-450
-42% -$29.3K ﹤0.01% 404
2019
Q3
$68K Hold
1,070
0.01% 331
2019
Q2
$72K Sell
1,070
-1,615
-60% -$106K 0.01% 330
2019
Q1
$207K Buy
+2,685
New +$178K 0.02% 189
2018
Q4
Sell
-2,685
Closed -$207K 260
2018
Q3
$207K Sell
2,685
-147
-5% -$11.1K 0.02% 189
2018
Q2
$201K Sell
2,832
-65,100
-96% -$4.6M 0.02% 192
2018
Q1
$4.99M Sell
67,932
-3,735
-5% -$297K 0.56% 48
2017
Q4
$5.13M Sell
71,667
-21,230
-23% -$1.61M 0.56% 48
2017
Q3
$7.69M Buy
92,897
+628
+0.7% +$48K 0.9% 31
2017
Q2
$6.53M Sell
92,269
-2,763
-3% -$184K 0.76% 37
2017
Q1
$6.46M Sell
95,032
-7,240
-7% -$509K 0.69% 38
2016
Q4
$7.32M Sell
102,272
-32,268
-24% -$2.4M 0.84% 34
2016
Q3
$106K Sell
134,540
-10,045
-7% -$816K 1.39% 24
2016
Q2
$12.1M Buy
144,585
+215
+0.1% +$19.1K 1.45% 16
2016
Q1
$13.3M Buy
144,370
+27,635
+24% +$2.49M 1.64% 12
2015
Q4
$11.8M Buy
116,735
+2,100
+2% +$219K 1.49% 14
2015
Q3
$11.2M Buy
114,635
+4,600
+4% +$511K 1.46% 15
2015
Q2
$12.9M Buy
110,035
+2,710
+3% +$296K 1.57% 14
2015
Q1
$10.5M Buy
107,325
+23,925
+29% +$2.43M 1.26% 18
2014
Q4
$7.86M Buy
83,400
+14,500
+21% +$1.5M 0.94% 34
2014
Q3
$7.33M Buy
68,900
+1,410
+2% +$138K 0.88% 37
2014
Q2
$5.6M Buy
67,490
+57,640
+585% +$4.49M 0.68% 47
2014
Q1
$698K Hold
9,850
0.09% 169
2013
Q4
$740K Hold
9,850
0.1% 160
2013
Q3
$619K Hold
9,850
0.09% 171
2013
Q2
$505K Buy
+9,850
New +$513K 0.07% 178

Other funds holding GILD

Salem Investment Counselors's GILD Position: Q2 2026 in Review

Salem Investment Counselors increased its Gilead Sciences (GILD) stake by 9.5% in Q2 2026, buying an estimated $15.8K and bringing the position to 1,389 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #420.

Salem Investment Counselors first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. The position peaked at $13.3M in Q1 2016. 1,323 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Salem Investment Counselors held 1,389 shares of Gilead Sciences worth $175K as of Q2 2026.
  • Salem Investment Counselors bought 120 Gilead Sciences shares in Q2 2026, an estimated $15.8K.
  • Gilead Sciences made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #420 holding.
  • Salem Investment Counselors first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
  • Salem Investment Counselors's Gilead Sciences position peaked at $13.3M in Q1 2016.
  • 1,323 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.